NordestgaardBG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res2016; 118(4): 547–563.
2.
VarboABennMTybjaerg-HansenA, et al.Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol2013; 61(4): 427–436.
3.
VarboANordestgaardBG. Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population. Ann Neurol2019; 85(4): 550–559.
4.
SuXKongYPengD. Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. Lipids Health Dis2019; 18(1): 134–134.
5.
BrunnerFJWaldeyerCOjedaF, et al.Consortium obotMCR. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet2019; 394: 2173–2183.
6.
FerenceBAKasteleinJJPGinsbergHN, et al.Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA2017; 318(10): 947–956.
7.
FerenceBAKasteleinJJPRayKK, et al.Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA2019; 321(4): 364–373.
8.
ElshazlyMBManiPNissenS, et al.Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease. Eur J Prev Cardiol. 2020; 27: 1091–1100.
9.
LinANerlekarNRajagopalanA, et al.Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography. Atherosclerosis2019; 284: 24–30.
10.
NichollsSJPuriRAndersonT, et al.Effect of Evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA2016; 316(22): 2373–2384.
11.
PuriRNichollsSJShaoM, et al.Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol2015; 65(13): 1273–1282.
12.
VarboABennMTybjaerg-HansenA, et al.Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation2013; 128(12): 1298–1309.
13.
NorataGDGrigoreLRaselliS, et al.Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a pro-inflammatory response in the endothelium: molecular mechanisms and gene expression studies. J Mol Cell Cardiol2006; 40(4): 484–494.
14.
IzumidaTNakamuraYHinoY, et al.Combined effect of small dense low-density lipoprotein cholesterol (sdLDL-C) and remnant-like particle cholesterol (RLP-C) on low-grade inflammation. J Atheroscler Thromb. Epub ahead of print 29 August 2019. DOI: 10.5551/jat.49528.
15.
NorataGDGrigoreLRaselliS, et al.Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis2007; 193(2): 321–327.
